Abstract

 
 
 
 Background: Breast Cancer is the most frequent malignancy in women with a rising incidence. Antibody-drug conjugates targeting HER2 and TROP-2 are new tools already effective against breast cancer but ADCs targeting new transmembrane receptors are necessary to overcome the dependence on HER-2 pathway. New trials are emerging fast as new ADCs are under investigation. Methods: We reviewed ClinicalTrials.gov and Pubmed for early clinical trials on new ADCs in clinical development for HER-2 negative breast cancer. Results: Trials testing 12 new molecules were found. Pre-clinical studies, safety and results in phase I/II trials published of each new molecule were reviewed and described briefly. Side effects regarding ADCs with maytansine derivatives (DM1/4) or auristatins (MMAE/MMAF) payloads were described. Conclusion: ADCs represent a practice-changing therapy for cancer treatment. New compounds against several new targets are expected to become part of clinical practice in the near future.
 
 
 
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Medical Science and Clinical Invention
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
